Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $42.33 Consensus Target Price from Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $42.3333.

Several research analysts recently issued reports on TYRA shares. William Blair assumed coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They set an “outperform” rating for the company. Barclays started coverage on Tyra Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating on the stock. Cantor Fitzgerald began coverage on Tyra Biosciences in a research note on Tuesday, February 24th. They set an “overweight” rating for the company. Wedbush boosted their price objective on Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Finally, Jefferies Financial Group raised their target price on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd.

Insider Buying and Selling at Tyra Biosciences

In other news, Director Robert J. More sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director directly owned 3,823,425 shares of the company’s stock, valued at $95,585,625. This represents a 0.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 15.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TYRA. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tyra Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the last quarter. AQR Capital Management LLC boosted its stake in Tyra Biosciences by 2.0% during the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock worth $753,000 after buying an additional 562 shares during the last quarter. MetLife Investment Management LLC boosted its stake in Tyra Biosciences by 5.0% during the fourth quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock worth $404,000 after buying an additional 725 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in Tyra Biosciences by 6.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock valued at $309,000 after buying an additional 741 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Tyra Biosciences by 5.8% in the 4th quarter. Deutsche Bank AG now owns 16,377 shares of the company’s stock valued at $431,000 after buying an additional 894 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Trading Up 2.9%

NASDAQ:TYRA opened at $34.74 on Friday. The firm has a fifty day simple moving average of $30.61 and a 200-day simple moving average of $21.59. Tyra Biosciences has a 12 month low of $6.42 and a 12 month high of $35.96. The company has a market capitalization of $1.87 billion, a P/E ratio of -17.28 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). Equities analysts forecast that Tyra Biosciences will post -1.57 EPS for the current year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.